

UCSF

UC San Francisco Previously Published Works

Title

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series.

Permalink

<https://escholarship.org/uc/item/9tm0882p>

Journal

Journal of Contemporary Brachytherapy, 16(1)

ISSN

1689-832X

Authors

Thomas, Horatio
Shaheen, Haitham
Sabbagh, Ali
[et al.](#)

Publication Date

2024-02-01

DOI

10.5114/jcb.2024.135645

Peer reviewed

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Horatio Thomas, MD¹, Jie Jane Chen, MD¹, Haitham Shaheen, MD², Ali Sabbagh, MD¹, Hasan Abdul-Baki, BS¹, Oi Wai Chau, PhD¹, Nauman Malik, MD³, Alan Ayoub, MD⁴, Comron Hassanzadeh, MD⁵, I-Chow Hsu, MD¹, Osama Mohamad, MD, PhD^{1,6}

¹Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA, ²Department of Clinical Oncology, Faculty of Medicine, Suez Canal University, Egypt, ³Department of Radiation Oncology, University of Toronto, Toronto, Canada,

⁴University of Zagreb School of Medicine, Zagreb, Croatia, ⁵Department of Radiation Oncology, MD Anderson Cancer Center, Houston, USA,

⁶Department of Urology, University of California San Francisco, San Francisco, CA, USA

Abstract

Introduction: Inflammatory bowel disease (IBD) is a relative contraindication to external beam radiation therapy (EBRT) for prostate cancer patients due to fear of increased risk of gastrointestinal (GI) toxicity. High-dose-rate (HDR) brachytherapy, capable of minimizing radiation dose to surrounding tissues, is a feasible alternative. Given limited data, this study examined the safety profile of HDR brachytherapy in this setting.

Material and methods: We conducted a retrospective review of patients with localized prostate cancer and IBD treated with HDR brachytherapy at the University of California San Francisco (UCSF), between 2010 and 2022. Eligibility criteria included biopsy-proven prostate cancer, no distant metastases, absence of prior pelvic radiotherapy, IBD diagnosis, and at least one follow-up visit post-treatment.

Results: Eleven patients were included, with a median follow-up of 28.7 months. The median dose administered was 2700 cGy (range, 1500-3150 cGy) over 2 fractions (range, 1-3 fractions). Two patients also received EBRT. Rectal spacers (SpaceOAR) were applied in seven patients. All patients experienced acute genitourinary (GU) toxicity, ten of which were grade 1 and one was grade 2. Eight patients experienced late grade 1 GU toxicity, and three patients had late grade 2 GU toxicity. GI toxicities were similarly low-grade, with six grade 1 acute toxicity, no grade 2 or higher acute toxicity, six grade 1 late toxicity, and one late grade 2 GI toxicity. No grade 3 or higher acute or late GI or GU toxicities were reported.

Conclusions: HDR brachytherapy appears to be a safe and tolerable treatment modality for patients with prostate cancer and IBD, with minimal acute and late GI and GU toxicity. These findings warrant multi-institutional validation due to small sample size.

J Contemp Brachytherapy 2024; 16, 1: 1-5
DOI: <https://doi.org/10.5114/jcb.2024.135645>

Key words: high-dose-rate, HDR, brachytherapy, prostate cancer, inflammatory bowel disease.

Purpose

Prostate cancer is the second most prevalent cancer and the fourth leading cause of cancer-related mortality in men worldwide [1]. Various therapeutic options, such as surgery and radiotherapy (RT), exist for treating patients with localized prostate cancer [2, 3]. The choice of treatment is influenced by a range of factors, including clinical and pathological characteristics of the tumor, patient comorbidities, life expectancy, and individual preferences [4]. Toxicity profiles of these treatment modalities often serve as additional criteria for tailoring patient-specific approaches, especially when comorbidities are present [2, 3].

Inflammatory bowel disease (IBD) is a relative contraindication to external beam radiation therapy (EBRT) due to concerns that radiation dose to prostate-rectal interface and small and large bowel could precipitate significant acute and late rectal and bowel toxicity. One study found an overall incidence of severe toxicity of 46% following abdominal and pelvic irradiation among patients with IBD, with 21% experiencing acute enteral toxicity that necessitated cessation of RT, and late toxicity requiring hospitalization or laparotomy due to complications of the small or large bowel [5]. Existing literature on the safety of EBRT in IBD patients with prostate cancer shows an association between EBRT and increased risk of gastroin-

Address for correspondence: Osama Mohamad, MD, PhD, Department of Radiation Oncology, Department of Urology, University of California San Francisco, 1825, 4th Street, San Francisco, California 94158, USA, phone: +1-415-476-9065, e-mail: omohama@gmail.com

Received: 29.10.2023

Accepted: 08.01.2024

Published: 23.02.2024

testinal (GI) toxicity, though perhaps somewhat mitigated with the use of a hydrogel rectal spacer [6, 7]. While advancements in radiation techniques have enabled more targeted delivery, EBRT still exposes the rectal-prostate interface and surrounding tissues in the lower pelvis to significant radiation. High-dose-rate brachytherapy (HDR-BT) is a precision-focused alternative that offers excellent local control while limiting dose to surrounding tissues [8, 9]. However, data on the safety of HDR-BT in patients with IBD is limited to small retrospective studies or institutional case series [10, 11].

This study aimed to evaluate the safety of HDR-BT, both as a monotherapy and as a boost to EBRT, in this specific patient cohort treated at the University of California San Francisco (UCSF).

Table 1. Baseline patients' characteristics

Characteristics	Number (range or %)
Median follow-up (months)	28.7 (range, 4.2-95.9)
NCCN risk grouping	
LR	2 (18.2)
UIR	5 (45.4)
HR	4 (36.4)
IBD	
UC	7 (63.6)
CD	4 (36.4)
Active disease	1 (9.1)
Rectum involved	
Yes	0
No	11 (100.0)
ADT	
Yes	5 (45.4)
No	6 (54.5)
Brachytherapy intent	
Definitive	11 (100.0)
Salvage	0
Median baseline IPSS (IQR)	8 (range, 3-26)
Baseline grade 1 GU symptoms	8 (73.0)
Baseline GI symptoms	
Grade 1	6 (55.0)
Grade 2	1 (9.0)
Previous abdominal and pelvic surgery	
Colectomy, ileal pouch	4 (36.4)
Proctocolectomy, ileal pouch	3 (27.3)
Hemicolectomy	1 (9.1)
EBRT	
Yes	2 (18.2)
No	9 (81.8)
Median brachytherapy dose (cGy)	2700 (range, 1500-3150)
Median brachytherapy fractions	2 (range, 1-3)

NCCN – National Comprehensive Cancer Network, LR – low-risk, UIR – unfavorable intermediate-risk, HR – high-risk, IBD – inflammatory bowel disease, UC – ulcerative colitis, CD – Crohn's disease, ADT – androgen deprivation therapy, IPSS – international prostate symptom score, GU – genitourinary, GI – gastrointestinal, EBRT – external beam radiotherapy

Material and methods

This study was done in accordance with institutional ethical standards and the Declaration of Helsinki, and was approved by the Institutional Review Board at UCSF (IRB approval No.: 20-31257). A retrospective chart review was performed to identify patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC), and treated for prostate cancer by two attending physicians at UCSF (OM and ICH) with HDR-BT between 2010 and 2022. Inclusion criteria were patients with biopsy-confirmed prostate cancer with no evidence of distant disease on clinical examination or imaging, no history of prior pelvic RT, and at least one post-HDR-BT treatment clinic appointment attended.

All patients received definitive HDR-BT at UCSF. Brachytherapy catheters were inserted through the perineum into the prostate using real-time trans-rectal ultrasound guidance. Sixteen catheters were implanted in all patients regardless of prostate cancer size, as previously described [12, 13]. Thereafter, patients underwent computed tomography (CT) of the pelvis for simulation and treatment planning. On CT images, the treating physician delineated the whole prostate clinical target volume (CTV) without margin and organs at risk (OARs), including the penile bulb, rectum, bladder, and intra-prostatic urethra. Seminal vesicles were included at the treating physician's discretion. CTV to planning target volume (PTV) margin was 0 mm. Treatment planning was performed using inverse planning simulated annealing (IPSA) (Oncentra Brachy, Elekta, Sweden). Treatment planning goals were defined as dose-volume normalized to prescription dose. Target goal for prostate PTV was 100% of the prescription to 95% (preferred, 90% required) of the volume. OARs planning goals included a urethra constraint of no more than 1 cc receiving $\geq 120\%$ of the prescription, and a maximum dose to 0.03 cc < 150% of the prescription. For the bladder and rectum or ileum in patients with prior colectomy, clinical goal was for < 1 cc receiving 75% of the prescription.

For this study, acute and late genitourinary (GU) and GI toxicities were retrospectively graded with common terminology criteria for adverse events (CTCAE), version 5. Toxicity was defined as acute if it occurred less than three months after completing radiation, and late toxicity was specified if it occurred more than three months later. Disease outcomes included post-treatment prostate specific antigen (PSA) and biochemical failure defined with Phoenix definition (nadir + 2 ng/ml) [14].

Results

Patients' characteristics are described in Table 1. The median follow-up was 28.7 months (range, 4.2-95.9 months). Seven patients (63.6%) had UC, and one patient (9.1%) had active CD. Androgen deprivation therapy (ADT) was used in five patients (45.4%), with a median duration of 18 months (range, 7-24 months). The median baseline IPSS score was 8 (range, 3-26). SpaceOAR® rectal spacer was applied in seven patients, while the other patients were treated before rectal spacers were common.

In all patients, HDR-BT was used as definitive treatment. Nine patients were treated with HDR-BT without EBRT, including six patients with 2700 cGy in 2 fractions, and three patients with 3150 cGy in 3 fractions. Two patients (18.2%) were treated with a combination of EBRT to the pelvis to 45 Gy in 25 fractions and HDR-BT to 15 Gy in 1 fraction. The median V95% and V90% of the prescription were 96.4% and 98.3%, respectively. All patients achieved rectal and bladder constraints (Figure 1 and Table 2).

All patients experienced acute GU toxicity, with ten patients (91%) experiencing grade 1 toxicity and one patient (9%) grade 2 toxicity (Table 3). The most common acute GU toxicity was urinary frequency (82% grade 1 and 18% grade 2), with 45% reporting nocturia. Grade 1 incontinence and urgency were reported in one patient (9%). Eight patients (73%) had late grade 1 GU toxicity, and three (27%) had grade 2 GU toxicity. The most frequently reported late toxicity was urinary frequency (45% grade 1 and 27% grade 2), with 36% reporting nocturia. One patient (9%) had grade 2 erectile dysfunction. One patient (9%) had grade 1 hematuria that only occurred once. No grade 3 or higher late toxicity was observed in this cohort. One patient, who experienced intermittent diminished urinary stream, dysuria, and hematuria at 15 months after completion of HDR-BT, underwent a cystoscopy, which showed a proximal bulbar

urethral stricture that prevented passage of a flexible cystoscope. Urinary cytology was negative for malignancy, and his urinary symptoms completely resolved without any intervention.

Six patients (54.5%) had grade 1 acute GI toxicity (Table 4). No grade 2 or higher acute GI toxicity was observed. Six patients (54.5%) experienced late grade 1 GI toxicity, and one patient (9.1%) had late grade 2 GI toxicity. Four patients experienced acute and late grade 1 diarrhea (36%). Two patients (18%) had acute rectal incontinence, one patient (9%) developed late rectal leakage, and one patient (9%) experienced low-grade dysplasia.

All patients achieved a PSA response to treatment. The six patients, who were treated without ADT had a median PSA of 6.6 ng/ml (range, 4.5-11.2 ng/ml) at diagnosis. At a median of 12 months after ADT initiation, these patients achieved a median PSA of 1.5 ng/ml (range, 0.4-3.4 ng/ml). No patient experienced biochemical or clinical recurrence, distant metastasis, or death from any cause.

Discussion

The current study investigated the safety, effectiveness, and tolerability of HDR-BT in patients with localized prostate cancer and IBD. Our cohort achieved nota-




Fig. 1. Axial, sagittal, and coronal plane dose distributions from a single-fraction of high-dose-rate (HDR) brachytherapy used to treat the prostate in a patient with a concurrent inflammatory bowel disease diagnosis. The suture line from a prior surgery is evident in the sagittal image

Table 2. Dosimetric parameters for patients treated with HDR brachytherapy

Patient	Prescribed fraction dose (cGy)	V95% prostate (% , cc)	V90% prostate (% , cc)	Rectum V75% (cc)	Bladder V75% (cc)	Rectal spacer present
1	1050	96.4%, 55.5 cc	99.2%, 57.2 cc	0.18	0.96	Yes
2	1350	90.5%, 43.5 cc	93.73%, 45.1 cc	0	0	Yes
3	1350	96.5%, 36.1 cc	98.3%, 43.0 cc	0	0.01	Yes
4	1050	70.3%, 54.6 cc	75.0%, 59.0 cc	0	0.92	Yes
5	1350	92.3%, 67.0 cc	95.0%, 68.9 cc	0.03	0.4	Yes
6	1350	96.6%, 96.0 cc	98.4%, 97.8 cc	0	1.01	No
7	1350	95.4%, 49.6 cc	97.2%, 50.5 cc	0.55	0.23	Yes
8	1350	98.3%, 54.6 cc	99.4%, 55.2 cc	0.45	0	No
9	1500	99.2%, 44 cc	99.9%, 44.24 cc	0.13	0.64	No
10	1500	97.8%, 30.3 cc	99.0%, 30.7 cc	0.27	0.01	Yes
11	1050	94.0%, 42.8 cc	98.0%, 44.6 cc	0	0.5	No

Table 3. Genitourinary toxicity grading after HDR brachytherapy

Toxicity	Grade	n (%)
Acute GU toxicity	1	10 (90.9)
	2	1 (9.1)
	3	0
	4	0
	5	0
Late GU toxicity	1	8 (72.7)
	2	3 (27.3)
	3	0
	4	0
	5	0

GU – genitourinary

Table 4. Gastrointestinal toxicity after HDR brachytherapy

Toxicity	Grade	n (%)
Acute GI toxicity	1	6 (54.5)
	2	0
	3	0
	4	0
	5	0
Late GI toxicity	1	6 (54.5)
	2	1 (9.1)
	3	0
	4	0
	5	0

GI – gastrointestinal

ble PSA responses in all patients, and none experienced severe GI or GU toxicities during a median follow-up of 28.7 months. This study adds to the literature supporting the safety of HDR brachytherapy in patients with IBD and localized prostate cancer.

Previous brachytherapy studies on patients with prostate cancer and IBD have primarily focused on the safety of low-dose-rate brachytherapy (LDR-BT), and have reported conflicting toxicity results [15, 16]. Grann *et al.* performed a retrospective analysis of six patients with prostate cancer and IBD treated with iodine-125 (¹²⁵I) LDR-BT, and reported no severe GI toxicity [17]. In a larger cohort of 24 patients treated with EBRT and LDR-BT, 17% of patients had grade 2 rectal toxicity, and no acute or late grade 3 or 4 rectal toxicity was reported [15]. In contrast, Pai *et al.* conducted a review of 13 patients treated with ¹²⁵I LDR-BT monotherapy, and reported grade 3 or higher acute and late GI toxicity in 23% and 15% of patients, respectively [18]. All patients in this study, who experienced severe GI toxicity had completed an endoscopic assessment or biopsy of the rectum related to IBD within 3 months of brachytherapy [18]. Avoidance of biopsies or endoscopic assessment within the first few months after brachytherapy may help reduce the risk of late GI toxicity related to instrumentation of recently irradiated tissue. In a recent systematic review on radiotherapy in 194 patients with IBD treated with various modalities, including LDR-BT, HDR-BT, EBRT, and stereotactic body radiotherapy, late grade 3 or higher GI toxicity rate was 2.3% [19]. Similarly, a report on patients with prostate cancer and IBD treated with radiation (two with brachytherapy monotherapy, and eight with EBRT and brachytherapy boost) showed that IBD located in the rectum and low body mass index were associated with more severe rectal toxicity within six months of radiation [20]. These data suggest that patients with rectal or recto-sigmoid involvement of IBD may be at higher risk of severe GI toxicity. However, Peters *et al.*'s cohort included 14 patients with rectal or recto-sigmoid involvement, and found that LDR-BT was well-tolerated without severe toxicity [15].

When compared with EBRT, brachytherapy has been associated with similar or improved GI toxicity in pa-

tients with prostate cancer and IBD. In a retrospective cohort study of 100 patients with IBD and prostate cancer, EBRT was associated with a two-fold increase in the rate of IBD flare, and there was no statistically significant difference in the rates of IBD flare when comparing EBRT vs. brachytherapy at 6 months (11.8% vs. 7.7%, $p = 1$) [21]. Tromp *et al.* conducted a systematic review on bowel toxicity in patients with IBD treated for cancer with RT. Eight studies were included, with three studies assessing the use of brachytherapy, in which 7% of patients received brachytherapy [22]. The authors found that brachytherapy had similar rates of toxicity in patients with and without IBD, while EBRT was associated with increased rates of acute and late toxicity. The incidence of grade 3 or higher acute bowel toxicity was 7% in brachytherapy studies compared with 20% in EBRT studies, with similar numbers for late bowel toxicity (5% for brachytherapy vs. 15% for EBRT). In our cohort, only two patients received EBRT, and no grade 3 or higher GU or GI toxicity was identified.

There is limited data suggesting that HDR-BT has a more favorable toxicity profile compared with LDR-BT. Mohammed *et al.* described the safety and tolerability of HDR-BT in a small retrospective cohort of 11 patients with prostate cancer and IBD, and reported grade 1 diarrhea in three patients, grade 1 proctitis in three patients, and no grade 2 or greater rectal toxicity [10]. They concluded that HDR-BT has a better toxicity profile relative to LDR-BT due to the inverse planning advantage of HDR-BT. Lehrich *et al.* reported on patients with prostate cancer and IBD, with 70% receiving a hydrogel rectal spacer at the time of EBRT with HDR-BT boost [7, 23]. No patient experienced severe acute or late proctitis or diarrhea [11]. In our cohort, seven patients received rectal spacers, and no severe GI toxicity was observed. The use of rectal spacers is encouraged in this patient population if feasible for protection of the anorectum.

Our study, however, has its limitations as a retrospective study with a small cohort, which is susceptible to selection bias and limited generalizability. The follow-up duration of 28.7 months is relatively short. Moreover, our cohort lacks patients with active IBD and rectal involvement, known to be potential predictors of GI toxicity. Fecal calprotectin level was not available for this study,

which can be a helpful surrogate marker of GI inflammation to help distinguish between IBD activity and radiation-related GI toxicity, given the high negative predictive value of calprotectin [24, 25]. Due to the cohort's small size, our study did not have sufficient statistical power to identify clinical or dosimetric predictors of GI toxicity or IBD flare-ups. Despite these limitations, our results show that HDR delivered with limited rectal dose is safe and well-tolerated in patients with prostate cancer and IBD, with a low-risk of IBD flare, GI toxicity, or GU toxicity.

Conclusions

HDR-BT delivered with limited rectal dose is a reasonable and safe definitive treatment for patients with localized prostate cancer and IBD, with low-risk of GI or GU toxicities.

Disclosure

The authors report no conflict of interest.

References

- Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; 71: 209-249.
- Neal DE, Metcalfe C, Donovan JL et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received. *Eur Urol* 2020; 77: 320-330.
- Hamdy FC, Donovan JL, Lane JA et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med* 2023; 388: 1547-1558.
- Mohler JL, Antonarakis ES, Armstrong AJ et al. Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2019; 17: 479-505.
- Willett CG, Ooi CJ, Zietman AL et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. *Int J Radiat Oncol Biol Phys* 2000; 46: 995-998.
- Song DY, Lawrie WT, Abrams RA et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. *Int J Radiat Oncol Biol Phys* 2001; 51: 455-459.
- Singh R, Jackson PS, Blake M et al. Minimal rectal toxicity in the setting of comorbid Crohn's disease following prostate cancer radiotherapy with a hydrogel rectal spacer. *Cureus* 2017; 9: e1533.
- Petro Soatti C, Delishaj D, D'Amico R et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience. *J Contemp Brachytherapy* 2020; 12: 533-539.
- Morton G, McGuffin M, Chung HT et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. *Radiother Oncol* 2020; 146: 90-96.
- Mohammed W, Hoskin P, Henry A et al. Short-term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease. *Clin Oncol (R Coll Radiol)* 2018; 30: 534-538.
- Lehrich BM, Moyses HM, Kawakubo A et al. Long-term toxicity of high dose rate brachytherapy in prostate carcinoma patients with inflammatory bowel disease. *Clin Oncol (R Coll Radiol)* 2019; 31: 399-400.
- Kim Y, Hsu ICJ, Pouliot J. Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer. *J Appl Clin Med Phys* 2007; 8: 1-13.
- Charra-Brunaud C, Hsu ICJ, Weinberg V et al. Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high-dose-rate brachytherapy using a computer model. *Int J Radiat Oncol Biol Phys* 2003; 56: 586-591.
- Roach M, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* 2006; 65: 965-974.
- Peters CA, Cesaretti JA, Stone NN et al. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. *Int J Radiat Oncol Biol Phys* 2006; 66: 424-429.
- Thompson E, Barrett W. Ultra-long-term toxicity of prostate brachytherapy. *Brachytherapy* 2021; 20: 595-600.
- Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. *Int J Radiat Oncol Biol Phys* 1998; 40: 135-138.
- Pai HH, Keyes M, Morris WJ et al. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. *Brachytherapy* 2013; 12: 126-133.
- Trotta M, Patel KR, Singh S et al. Safety of radiation therapy in patients with prostate cancer and inflammatory bowel disease: A systematic review. *Pract Radiat Oncol* 2023; 13: 454-465.
- Annede P, Seisen T, Klotz C et al. Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. *J Gastrointest Oncol* 2017; 8: 173-179.
- Feagins LA, Kim J, Chandrakumaran A et al. Rates of adverse IBD-related outcomes for patients with IBD and concomitant prostate cancer treated with radiation therapy. *Inflamm Bowel Dis* 2020; 26: 728-733.
- Tromp D, Christie DRH. Acute and late bowel toxicity in radiotherapy patients with inflammatory bowel disease: A systematic review. *Clin Oncol (R Coll Radiol)* 2015; 27: 536-541.
- Vanneste BGL, Van Limbergen EJ, Marcelissen T et al. Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? *Clin Transl Radiat Oncol* 2021; 27: 121-125.
- D'Amico F, Rubin DT, Kotze PG et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. *United European Gastroenterol J* 2021; 9: 451-460.
- Kapel N, Ouni H, Benahmed NA et al. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. *Clin Transl Gastroenterol* 2023; 14: e00617.